Body Pharm BPC 157 5 Vial

The Body Pharm BPC-157 5 Vial is a 5 mg lyophilised research peptide, SKU bpbpc5, currently InStock at BeSkinny. It ships cold-chain to addresses within South Africa. See the product page for the current price.

Each batch comes with its own documentation and has been tested by an independent third party for purity and identity. You can view the Certificate of Analysis on the product page or request it by email. Orders paid before 12:00 on a business day usually dispatch the same day — one working day to major cities, two to five working days to outlying regions. We accept EFT, card and Bitcoin. Email support replies within 24 hours on weekdays; WhatsApp support operates 08:00–16:00, Monday to Friday.

Regulatory status: SAHPRA issued a public warning on 26 May 2026, updated 5 October 2026, which includes BPC-157 among unregistered peptide products marketed unlawfully in South Africa. The World Anti-Doping Agency (WADA) 2026 Prohibited List classifies it under S0 (non-approved substances), banning it at all times for athletes under the World Anti-Doping Code.

What the listing and CoA can verify

South African buyers can cross-reference three documents: the product listing, the physical vial label and the batch-specific Certificate of Analysis (CoA). The BeSkinny listing specifies a 5 mg lyophilised research peptide with SKU bpbpc5. The vial label should display the compound name, the declared amount, its physical form and a unique batch number. The CoA, available for each batch, provides results from independent purity and identity testing.

Document	Verification provided	Limitations
Body Pharm listing	Product name, format (lyophilised powder), stated amount (5 mg), price, stock status	Clinical effectiveness, approved human dosage, sterility, legal status for therapy
Vial label	Printed product name, amount, batch number, storage instructions	Purity test results, identity confirmation, independent verification
Batch-specific CoA	Purity percentage, identity testing (e.g., HPLC, mass spec), test date, laboratory, specification compliance	Human safety, approved uses, suitability for injection

The CoA must correspond to the batch number on your vial. We subject every batch to third-party purity and identity testing; request the CoA for your specific batch to check the test date and laboratory. Our Certificate of Analysis verification guide explains how to interpret these documents.

For other strengths or formats, the full BPC-157 South Africa range lists available options.

BPC-157 benefits: tendon and gut evidence

As of 2026, BPC-157 is an investigational peptide without any SAHPRA-approved human indication for tendon, ligament or gut conditions. Human evidence comes from a few small pilot studies, while interest in tendon and gut applications stems from animal models and proposed laboratory mechanisms. Descriptions of support or recovery on product pages are seller claims, not proven clinical facts.

Evidence level	Current literature (2026)	Limitations
Human evidence	A 2025 systematic review identified one small clinical report with 12 participants for knee pain and three pilot studies covering interstitial cystitis and pharmacokinetics; no large, controlled efficacy trials are available.	Effects on human tendon, ligament or gut outcomes.
Animal research	2025 reviews cite preclinical findings in models of muscle, tendon, ligament and bone injury, alongside proposed mechanisms like angiogenesis and fibroblast activity; gastrointestinal findings are still confined to animal studies.	Human treatment outcomes, approved uses, or assured results.
Seller claims	Our product page may frame BPC-157 within investigational contexts for tendon, ligament or gut-lining research; this is not a statement of clinical fact.	Efficacy, safety, or a lawful therapeutic use under SAHPRA.

BPC-157 has no established human dosage or registered indication in South Africa. A 5 mg lyophilised vial is strictly for research purposes. Researchers comparing recovery-related peptides may also consider the Body Pharm IGF 1LR3 100 Vial or the Body Pharm NAD+ 1000 Pen as alternative wellness and performance compounds.

BPC-157 versus TB-500: should you stack them?

Combining BPC-157 and TB-500 is not necessarily better than using either compound alone. No human clinical evidence proves that stacking them improves outcomes, and both peptides are unregistered research substances under SAHPRA's 2026 warning.

Criterion	BPC-157	TB-500
Common research focus in marketing	Studies on tendon, ligament and gut-related tissue	Studies on muscle, wound healing and cell migration
Evidence status	35 of 36 identified studies are preclinical; one 2025 clinical pilot had 12 participants with knee pain	Mainly animal and cell studies; no large human efficacy trials found
Documentation to check	Batch-specific CoA for purity and identity; request before buying	Equivalent third-party testing; confirm independently
Purchase decision	For single-compound research	For single-compound research
Stack consideration	No evidence-based approved combination; seller claims are not clinical proof	Same limitation applies

Both compounds are named in SAHPRA's 26 May 2026 notice on unregistered peptide products. WADA's 2026 Prohibited List places BPC-157 under S0 (non-approved substances) from 1 January 2026; TB-500 carries a similar risk and athletes must check the current status.

We stock both compounds separately for research use. Buyers needing guidance on reconstitution can use our how to reconstitute peptides with bacteriostatic water guide, or browse the full peptide and GLP-1 range to compare options.

Sources

• Peptide Products – Public Information, SAHPRA, 2026 — sahpra.org.za
• BPC-157 lacks human efficacy data for tendon repair, Pharma Journal, 2026
• Body Pharm Peptides South Africa, BeSkinny, 2026